Trial ID or NCT#

NCT02253992

Status

RECRUITING

Purpose

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Official Title

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Shivaani Kummar, MD, FACP
Medical oncologist, Sarcoma specialist
Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford) at the Stanford University Medical Center
Susan M. Swetter, MD
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist, Melanoma specialist
Professor of Dermatology at Palo Alto Veterans Affairs Health Care System and the Stanford University Medical Center
Bernice Kwong
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist
Clinical Associate Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

Kristine McGlennen
(650) 723-3589